Table 3.
Multivariate analysis of DFS and OS of MBC and TNBC
| Characteristic | DFS | OS | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P-value | HR | 95% CI | P-value | |
| MBC vs. TNBC | 1.99 | (1.01–3.83) | 0.05 | 1.50 | (0.75–2.97) | 0.250 |
| T2 vs. T1 | 2.34 | (1.44–3.94) | 0.001 | 2.34 | (1.41–3.88) | 0.001 |
| T3 vs. T1 | 2.07 | (1.01–4.28) | 0.048 | 2.52 | (1.22–5.19) | 0.012 |
| T4 vs. T1 | 7.35 | (1.96–27.56) | 0.003 | 10.39 | (2.88–37.51) | <0.001 |
| N (Positive vs. Negative) | 3.53 | (2.21–5.65) | <0.001 | 2.80 | (1.75–4.47) | <0.001 |
| Neoadjuvant, Yes vs. No | 3.39 | (2.01–5.74) | <0.001 | 3.45 | (2.07–5.75) | <0.001 |
| Radiation, No vs. Yes | 2.19 | (1.30–3.71) | 0.003 | 2.17 | (1.29–3.67) | 0.004 |
| Chemotherapy, No vs. Yes | 1.84 | (0.94–3.61) | 0.076 | 1.67 | (0.84–3.33) | 0.144 |
MBC Metaplastic breast cancer, TNBC Triple negative breast cancer; DFS, disease free survival; OS, overall survival